Bolivia vs Ghana: Average cost of drugs for extensively drug-resistant tuberculosis
Bolivia
753 constant 2022 US$
in 2024
Ghana
800 constant 2022 US$
in 2024
Bolivia rank
48th
Ghana rank
47th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bolivia
- Ghana
How they compare
Ghana currently reports 800 constant 2022 US$ against 753 constant 2022 US$ in Bolivia, a difference of 47 constant 2022 US$.
That makes Ghana's figure about 1.1 times Bolivia's.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Bolivia ahead.
Bolivia ranks 48th and Ghana ranks 47th of 56 countries.
Bolivia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bolivia | Ghana | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,454 constant 2022 US$ | 2,000 constant 2022 US$ | 7,454 constant 2022 US$ | Bolivia |
| 2020s | 8,250 constant 2022 US$ | 1,143 constant 2022 US$ | 7,106 constant 2022 US$ | Bolivia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bolivia or Ghana?
- Ghana, at 800 constant 2022 US$ against 753 constant 2022 US$ in Bolivia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bolivia and Ghana?
- 47 constant 2022 US$, with Ghana ahead.
- How many years of comparable data are there for Bolivia and Ghana?
- 5 years are reported by both, from 2018 to 2024.
- How do Bolivia and Ghana rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bolivia ranks 48th and Ghana ranks 47th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.